No abuse potential shown in preclinical studies
We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Key outcomes from the preclinical studies:
- No abuse potential: PN6047 displayed no signs of abuse potential in animal models, marking a notable departure from conventional opioids.
- Alleviates the opioid withdrawal syndrome: PN6047 mitigated symptoms associated with opioid withdrawal in animal models.
These studies, conducted in collaboration with Washington University and the University of Michigan and supported by the US National Institute of Drug Abuse, represent a significant step forward in our mission to provide safe and effective pain relief without the risk of addiction or severe side effects. As we gear up for Phase II clinical trials in 2024, our commitment to redefining pain management remains unwavering.
No abuse potential shown in preclinical studies
We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Key outcomes from the preclinical studies:
- No abuse potential: PN6047 displayed no signs of abuse potential in animal models, marking a notable departure from conventional opioids.
- Alleviates the opioid withdrawal syndrome: PN6047 mitigated symptoms associated with opioid withdrawal in animal models.
These studies, conducted in collaboration with Washington University and the University of Michigan and supported by the US National Institute of Drug Abuse, represent a significant step forward in our mission to provide safe and effective pain relief without the risk of addiction or severe side effects. As we gear up for Phase II clinical trials in 2024, our commitment to redefining pain management remains unwavering.
Latest news
View all
PharmNovo live at neurology theme event at RedEye
Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.
Read more
PharmNovo at the LSX Nordic Congress
PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:
Read more
17.5 MEUR blended funding from EIC
PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read more
PharmNovo presenting at the Global Forum
On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read more